TABLE 1.
Characteristic | Trastuzumab protein dose
|
All patients | |
---|---|---|---|
5 mg | 50 mg | ||
No. of patients | 2 | 6 | 8 |
| |||
Age (years) | |||
median | 60 | 54 | 56 |
range | 44-75 | 39-69 | 39-75 |
| |||
No. of patients | |||
Prior anti-HER2 therapy | |||
none | 1 | 1 | |
adjuvant trastuzumab | 1 | 2 | 3 (14, 18, 18)† |
trastuzumab for metastasis | 1 | 3 | 4 (4, 6, 14, 18)† |
| |||
Hormone receptor and HER2 status of recurrent disease | |||
ER and/or PR positive | 1 | 3 | 4 |
ER and PR negative | 1 | 3 | 4 |
HER2 | |||
IHC3+ | 2 | 5 | 7 |
IHC2+/FISH positive | 1 | 1 | |
| |||
Sites of metastatic disease | |||
bone | 2 | 4 | 6 |
lymph nodes | 2 | 5 | 7 |
liver | 2 | 2 | 4 |
lung | 1 | 1 | 2 |
pleural effusion | 1 | 1 | |
breast | 2 | 2 |
months since last anti-HER2 therapy administration
ER = estrogen receptor; PR = progesterone receptor;
IHC = immunohistochemistry; FISH = fluorescence in situ hybridization